Skip to main content

ASCO 2017 - Acute Myeloid Leukemia

ASCO 2017 - Acute Myeloid Leukemia

Differentiation Syndrome Associated with Enasidenib, a Selective Inhibitor of mIDH2

ASCO 2017 - Acute Myeloid Leukemia

Outcomes with Lower-Intensity Therapy in TP53-Mutated AML

ASCO 2017 - Acute Myeloid Leukemia

Enasidenib in Mutant-IDH2 Relapsed or Refractory AML: Results of a Phase 1 Dose-Escalation and Expansion Study

ASCO 2017 - Acute Myeloid Leukemia

Using a Synthetic Control Arm to Establish Early End Points as Indicators of Overall Survival in Acute Myeloid Leukemia

ASCO 2017 - Acute Myeloid Leukemia

Sorafenib plus 5-Azacytidine in Older, Untreated FLT3-ITD–Positive Patients with Acute Myeloid Leukemia

ASCO 2017 - Acute Myeloid Leukemia

Achievement of a Negative MRD State After Hypomethylating Agent Therapy in Older Patients with AML to Reduce Risk of Relapse

ASCO 2017 - Acute Myeloid Leukemia

Assessment of Molecular Response to Gilteritinib in FLT3 Mutation–Positive Relapsed/Refractory Acute Myeloid Leukemia

ASCO 2017 - Acute Myeloid Leukemia

Distinct Patterns of Somatic Mutation Clearance and Association with Clinical Outcome in Patients with AML

ASCO 2017 - Acute Myeloid Leukemia

Prognostic Modeling to Predict Outcomes in Older Patients with AML

ASCO 2017 - Acute Myeloid Leukemia

A Randomized Phase 2 Study Evaluating Idarubicin and Cytarabine with Clofarabine or Fludarabine in Adults with Newly Diagnosed AML

Page 1 of 2
Results 1 - 10 of 16